SynAct Pharma: New Indication Provides Diversification - Redeye
Bildkälla: Stockfoto

SynAct Pharma: New Indication Provides Diversification - Redeye

Redeye updates its base case of Synact following the directed share issue and new programme in polymyalgia rheumatica, which broadens resomelagon’s potential and diversifies its clinical development risk.

Redeye updates its base case of Synact following the directed share issue and new programme in polymyalgia rheumatica, which broadens resomelagon’s potential and diversifies its clinical development risk.
Börsvärldens nyhetsbrev